Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | MMP8 | P22894 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | LAP3 | P28838 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498585 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MEN1LMNAKMT2AMMP9 | |
| SCHEMBL17305535 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL21895921 | 0.83 | MMP2 (0.58) | ALDH1A1MEN1LMNAKMT2AMMP9 | |
| SCHEMBL31116669 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL31634304 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL12393791 | 0.82 | MMP9 (0.51) | ALDH1A1MEN1LMNAKMT2AMMP9 | |
| SCHEMBL13833235 | 0.82 | MMP9 (0.51) | ALDH1A1MEN1LMNAKMT2AMMP9 | |
| SCHEMBL12226978 | 0.82 | MMP9 (0.51) | ALDH1A1MEN1LMNAKMT2AMMP9 | |
| SCHEMBL17948521 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1LMNAKMT2AMMP9 | |
| SCHEMBL22475309 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1LMNAKMT2AMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234205-A1 | Antineoplastic peptides | BCL2A1, ETF1, BAK1 | ALDH1A1 4381/4885MEN1 1274/4885LMNA 1915/4885 |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | BCL2A1, CSTB, BAK1 | ALDH1A1 4287/4885MEN1 994/4885LMNA 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.